Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...

Cumberland Pharmaceuticals receives US FDA expanded indication approval for Caldolor injection: Nashville, Tennessee Friday, April 17, 2026, 17:00 Hrs [IST] Cumberland Pharmaceuti ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

Long-term partnership secures high-quality active pharmaceutical ingredient supply for Lasix(R) ONYU and future pipeline products BURLINGTON, Mass. and VICENZA, Italy, April 15, 2026 /PRNewswire/ -- ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication ...

Footage shows staff injecting without gloves and reusing syringes, but the hospital boss refuses to acknowledge it is genuine ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO ...

CEO Ben Palleiko told investors at Needham & Company’s 25th Annual Healthcare Conference that the company has seen a strong ...

Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and ...

Mo-Rez achieved confirmed objective response rates of 62% in patients with platinum-resistant ovarian cancer. Credit: MMD ...

With a single fee, new patients can start their journey on a comprehensive, holistic wellness plan based on personal health measures, with the full cost applied to the first treatment. WEST PALM BEACH ...